<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379934</url>
  </required_header>
  <id_info>
    <org_study_id>KetoCard01</org_study_id>
    <nct_id>NCT04379934</nct_id>
  </id_info>
  <brief_title>Functional and Metabolic Effects of Ketone Bodies on Human Atrial Tissue in Patients With and Without Heart Failure</brief_title>
  <official_title>Functional and Metabolic Effects of Ketone Bodies on Human Atrial Tissue in Patients With and Without Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proof of concept study aims to evaluate the effects of applying ketone bodies to human
      atrial tissue biopsies using an atrial strips model and high resolution respirometry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ketone bodies are high energy molecules which are naturally occurring in the body during
      fasting or stress.

      Recently, ketone bodies have been shown to improve cardiac function in patients with heart
      failure(1) through a mechanism, which has yet to be elaborated.

      We wish to evaluate the effects of ketone body administration on cardiac tissue subjected to
      ischemia reperfusion injury. We will evaluate contractile force of the and the mitochondrial
      performance. Cardiac atrial tissue will be obtained from patients undergoing coronary artery
      bypass grafting (CABG) or valve replacement surgery. Patients will be recruited after signing
      an informed consent and allocated in heart failure / non-heart failure groups based on a
      clinical evaluation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Contractile force recovery</measure>
    <time_frame>Outcome will be assessed within a year when the inclusion of patients is complete</time_frame>
    <description>Atrial strips model, contractile force (nm*mm^-1) during stabilization, ischemia and reperfusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial respiratory capacity</measure>
    <time_frame>Outcome will be assessed within a year when the inclusion of patients is complete</time_frame>
    <description>High Resolution Respirometry, Complex I and Complex I+II respiration (pmol O2 · s-1·mg-1) assessed via a substrate and inhibitor (SUIT) protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial Reactive Oxygen Species production</measure>
    <time_frame>Outcome will be assessed within a year when the inclusion of patients is complete</time_frame>
    <description>High Resolution FluoRespirometry, Complex I and Complex I+II linked ROS generation measured with AmplexUltra red and H2O2 interaction fluorescense</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Heart Failure</condition>
  <condition>Ischemia Reperfusion Injury</condition>
  <condition>Mitochondrial Pathology</condition>
  <arm_group>
    <arm_group_label>Heart failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ejection fraction &lt; 45%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-heart failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Ejection fraction &gt; 45%</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3-hydroxybuturate</intervention_name>
    <description>3-hydroxybuturate will be administered directly as a modified Krebs Henseleit buffer in a super perfused atrial strips model</description>
    <arm_group_label>Heart failure</arm_group_label>
    <arm_group_label>Non-heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  EF &lt; / &gt; 45%, hospitalized for elective CABG or heart valve surgery

        Exclusion Criteria:

          -  Myocardial infarction within 4 weeks, atrial fibrillation, medically treated thyroid
             disease, oral treatment with opioids.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans Erik Bøtker, M.D., Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacob Seefeldt, B.M</last_name>
    <phone>+45 41178633</phone>
    <email>jacob.seefeldt@clin.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bent Roni Nielsen, M.D., PhD.</last_name>
    <phone>+45 51 21 93 63‬</phone>
    <email>bent.nils@midt.rm.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacob Seefeldt, M.B.</last_name>
      <phone>+45 4117633</phone>
      <email>jacob.seefeldt@clin.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Bent Roni Nielsen, M.D., Ph.D.</last_name>
      <phone>+45 51219363</phone>
      <email>bent.nils@midt.rm.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Bent Roni Nielsen, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacob Seefeldt, M.B</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Nielsen R, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, Harms HJ, Frøkiær J, Eiskjaer H, Jespersen NR, Mellemkjaer S, Lassen TR, Pryds K, Bøtker HE, Wiggers H. Cardiovascular Effects of Treatment With the Ketone Body 3-Hydroxybutyrate in Chronic Heart Failure Patients. Circulation. 2019 Apr 30;139(18):2129-2141. doi: 10.1161/CIRCULATIONAHA.118.036459.</citation>
    <PMID>30884964</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

